New guidelines reiterate need for abuse deterrent technologies and call for enabling clinicians to provide comprehensive pain management including appropriate use of opioid medicationsORLANDO, FL / ACCESSWIRE
ORLANDO, FL / ACCESSWIRE / October 26, 2022 / Nutriband Inc. (the "Company") (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that its subsidiary, 4P Therapeutics LLC ("4P Therapeutics"), has conducted a Phase
ORLANDO, FL / ACCESSWIRE / September 8, 2022 / Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, today announced financial and operational results for the second quarter
ORLANDO, FL / ACCESSWIRE / August 16, 2022 / Nutriband Inc. announced today that the 7:6 forward split of its common stock was effective at the opening of trading on Friday, August 12,. | August 16, 2022
ORLANDO, FL / ACCESSWIRE / August 10, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) ("Nutriband" or the "Company") announced on July 27, 2022 that its Board of Directors had approved and declared a